Raltegravir: an integrase inhibitor for HIV-1

Bibliography

• Epidemiology of HIV/AIDS – United States, 1981–2005. MMWR Morb Mortal Wkly Rep 2006;55:589-92
   PubMedGoogle Scholar
• Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60
   PubMed Web of Science ®Google Scholar
• Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-6
   PubMed Web of Science ®Google Scholar
• Pakker NG, Notermans DW, de Boer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998;4:208-14
   PubMed Web of Science ®Google Scholar
• Wong JK, Gunthard HF, Havlir DV, et al. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proc Natl Acad Sci USA 1997;94:12574-9
   PubMed Web of Science ®Google Scholar
• Zhang ZQ, Notermans DW, Sedgewick G, et al. Kinetics of CD4+ T cell repopulation of lymphoid tissues after treatment of HIV-1 infection. Proc Natl Acad Sci USA 1998;95:1154-9
   PubMed Web of Science ®Google Scholar
• WHO. Joint United Nations Programme on HIV/AIDS – Global facts and figures. Geneva: World Health Organization; 2006
   Google Scholar
• AIDSinfo. Offering information on HIV/AIDS treatment, prevention and research. Available at: http://aidsinfo.nih.gov
   Google Scholar
• Merck & Co. I. Highlights of prescribing information – Isentress™ (raltegravir) tablets. 2007. Available at: http://www.merck.com/product/usa/pi_circulars/i/isentress/isentress_pi.pdf [Last accessed 4 February 2008]
   Google Scholar
• Summa V, Pace P, Petroccci A, et al. Discovery of MK-0518 a novel, potent and selective HIV integrase inhibitor in Phase III clinical trials. Presented at 16th AIDS International Conference. Toronto, Canada; 2006
   Google Scholar
• Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007;4:125-33
   Google Scholar
• Bukrinsky MI, Sharova N, McDonald TL, et al. Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection. Proc Natl Acad Sci USA 1993;90:6125-9
   PubMed Web of Science ®Google Scholar
• Asante-Appiah E, Skalka AM. HIV-1 integrase: structural organization, conformational changes, and catalysis. Adv Virus Res 1999;52:351-69
   PubMed Web of Science ®Google Scholar
• Esposito D, Craigie R. HIV integrase structure and function. Adv Virus Res 1999;52:319-33
   PubMed Web of Science ®Google Scholar
• Wainberg MA, Kendall O, Gilmore N. Vaccine and antiviral strategies against infections caused by human immunodeficiency virus. CMAJ 1988;138:797-807
   PubMed Web of Science ®Google Scholar
• Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov 2005;4:236-48
   PubMed Web of Science ®Google Scholar
• Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000;287:646-50
   PubMed Web of Science ®Google Scholar
• Wai JS, Egbertson MS, Payne LS, et al. 4-Aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells. J Med Chem 2000;43:4923-6
   PubMed Web of Science ®Google Scholar
• Grobler JA, Stillmock K, Hu B, et al. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc Natl Acad Sci USA 2002;99:6661-6
   PubMed Web of Science ®Google Scholar
• Marchand C, Johnson AA, Karki RG, et al. Metal-dependent inhibition of HIV-1 integrase by beta-diketo acids and resistance of the soluble double-mutant (F185K/C280S). Mol Pharmacol 2003;64:600-9
   PubMed Web of Science ®Google Scholar
• Hazuda DJ, Young SD, Guare JP, et al. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 2004;305:528-32
   PubMed Web of Science ®Google Scholar
• Summa V, Petrocchi A, Matassa VG, et al. 4,5-Dihydroxypyrimidine carboxamides and N-alkyl-5-hydroxypyrimidinone carboxamides are potent, selective HIV integrase inhibitors with good pharmacokinetic profiles in preclinical species. J Med Chem 2006;49:6646-9
   PubMed Web of Science ®Google Scholar
• Savarino A. A historical sketch of the discovery and development of HIV-1 integrase inhibitors. Expert Opin Investig Drugs 2006;15:1507-22
   PubMed Web of Science ®Google Scholar
• Kassahun K, McIntosh I, Cui D, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 2007;35:1657-63
   PubMed Web of Science ®Google Scholar
• Iwamoto M, Wenning LA, Petry AS, et al. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Mol Ther 2008;83:293-9
   Google Scholar
• Markowitz M, Morales-Ramirez JO, Nguyen BY, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 2006;43:509-15
   PubMed Web of Science ®Google Scholar
• Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a Phase II randomised controlled trial. Lancet 2007;369:1261-9
   PubMed Web of Science ®Google Scholar
• Cooper D, Gatell J, Rockstroh J, et al. Results of BENCHMRK-1, a Phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, USA; 2007 (Abstract 105aLB)
   Google Scholar
• Steigbigel R, Kumar P, Eron J, et al. Results of BENCHMRK-2, a Phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, USA; 2007 (Abstract 105bLB)
   Google Scholar
• Merck & Co. I. FDA Antiviral Drugs Advisory Committee Meeting. ISENTRESS™ (raltegravir) 400 mg for treatment of HIV (NDA 22-145). 2007. Available at: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4314b1-01-Merck.pdf
   Google Scholar
• Hazuda D, Miller M, Nguyen B, Zhao J. Resistance to the HIV-integrase inhibitor raltegravir: analysis of protocol 005, a Phase II study in patients with triple-class resistant HIV-1 infection. XVI International HIV Drug Resistance Workshop. Barbados; 2007 (Abstract 8)
   Google Scholar
• Iwamoto M, Wenning L, Petry A, et al. Minimal effect of ritonavir and efavirenz on the pharmacokinetics of MK-0518. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA; 2006 (Abstract A-0373)
   Google Scholar
• Wenning L, Friedman E, Kost J, et al. Lack of a significant drug interaction between MK-0518 and tenofovir disoproxil fumarate. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA; 2006 (Abstract A-0375)
   Google Scholar
• Wenning L, Hanley H, Stone J, et al. Effect of tipranavir + ritonavir on pharmacokinetics of MK-0518. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA; 2006 (Abstract A-0374)
   Google Scholar
• Anderson M, Kakuda T, Miller J, et al. Pharmacokinetic evaluation of non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC125 and integrase inhibitor (InSTI) raltegravir (RAL) in healthy subjects. 4th International AIDS Society (IAS) Conference. Sydney, Australia; 2007 (Abstract TUPDB02)
   Google Scholar
• Kumar P, Cooper D, Steigbigel R, et al. Efficacy of raltegravir, an HIV integrase inhibitor, in combination with regimens containing enfuvirtide, darunavir, or tipranavir in patients with triple-class resistant virus: combined results from BENCHMRK-1 and BENCHMRK-2. 11th European AIDS Conference. Madrid, Spain; 2007 (Abstract P7.2/06)
   Google Scholar
• FDA. FDA approves new HIVdrug – raltegravir tablets used in combination with other antiretroviral agents. FDA News 2007
   Google Scholar
• Merck & Co. I. Isentress™ (raltegravir) tablets. Stocking card. 2007. Available at: http://www.isentress.com/raltegravir/isentress/index.jsp
   Google Scholar
• NCBI website. Available at: http://www.ncbi.nlm.nih.gov
   Google Scholar
• FDA website on drugs used in the treatment of HIV infection. Available at: http://www.fda.gov/oashi/aids/virals.html
   Google Scholar